Diagnosis and treatment of mucosa Candida spp. infections – a review article

Marta Dąbrowska, Monika Sienkiewicz, Paweł Kwiatkowski, Michał Dąbrowski


Candida albicans is the most common cause of fungal infections worldwide. Non-albicans Candida species play an important role in vulvovaginal candidiasis and invasive infections. Most cases of infections are endogenous. In case of patients with immune disorders this opportunistic pathogen causes both surface, systemic infections, and candidemia. Symptoms depend on the area affected. Candidiasis are treated with antimycotics; these include clotrimazole, nystatin, fluconazole, voriconazole, amphotericin B, and echinocandins. The emergence of drug resistance and the side effects of currently available antifungals are becoming a major problem in the management of Candida spp. infection.


Candida spp., mucosa, treatment, recommendation

Full Text:



Achkar J.M., Fries B.C. 2010. Candida infection of the genitourinary tract. Clin. Microbiol. Rev. 23: 253–73.

Anderson MR. 2004. Evaluation of vaginal complaints. JAMA. 291: 1368–1379.

Baran E. (ed). 1998. Zarys mikologii lekarskiej. Volumed, Wrocław.

Berberi A., Noujeim Z., Aoun G. 2015. Epidemiology of oropharyngeal candidiasis in Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome patients and CD4+ counts. J. Int. Oral Health. 7(3): 20–23.

Berek J.S. Berek and Novak’s gynecology. c2012. 15th ed. Philadelphia: Lipincott, Williams & Wilkins.

Brown S.J. 2009. Efficacy of fluconazole for the treatment of onychomycosis. Ann. Pharmacother. 43(10): 1684–1691.

Daniell H.W. 2016. Acid suppressing therapy as a risk factor for Candida esophagitis. Dis. Esophagus. 29: 479–483.

Edward L.L., Feldman M. Gastritis and other gastropathies. In: M. Feldman, L.S. Friedman, M.H. Sleisenger (ed.). Sleisenger & Fordtran’s gastrointestinal and liver disease, 7th ed. Elsevier Science, Philadelphia 2002: 810–827.

Edwards J.E. Jr. Candida species. In: G.L. Mandell, J.E. Bennett, R. Dolin (eds). Mandell, Bennett, & Dolin: Principles and Practice of Infectious Diseases, 6th ed. Elsevier Churchill Livingstone, Philadelphia 2005: 2939–2957.

Erdogan A., Rao S.S. 2015. Small intestinal fungal overgrowth. Curr. Gastroenterol. Rep. 17(4): 16. doi: 10.1007/s11894-015-0436-2.

Espinel-Ingroff A., Arendrup M., Cantón E., Cordoba S., Dannaoui E., García-Rodríguez J., Gonzalez G. M., Guarro J., Las-Flord C., Lackhard S,L., Martin-Mazuelos E., Meis J.F., Ostrovsky-Zeichner L., Pelaez T., St-Germain G., Turnidge J. 2017. Multicenter study of method-dependent epidemiological cutoff values for detection of resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest agar diffusion method. Antimicrob. Agents Chemother. 61(1):e01792-16.

Fan S, Liu X, Wu C, Xu L, Li J. 2015. Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia. 179(1–2): 95–101.

Gajewski P., Szczeklik (eds.) 2016. Grzybica przełyku. In: Interna Szczeklika. Kraków. Rozdz. III. C. 9.1.

Garczewska B., Kamińska W., Dzierżanowska D. 2008. Phenotype and genotype characterization of Candida albicans strains isolated from patients hospitalized at the Children’s Memorial Health Institute. Med. Dośw. Mikrobiol. 60: 231–241.

Gudlaugsson O. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37: 1172–1177.

Jabłońska S., Chorzelski T. 2002. Choroby skóry. Wyd. 5, PZWL, Warszawa 2002: 72–92.

Klotz S.A. 2006. Oropharyngeal candidiasis: a new treatment option. Clin. Infect. Dis. 15; 42(8): 1187–1188.

Kodsi B.E., Wickremesinghe C., Kozinn P.J., Iswara K., Goldberg P.K. 1976. Candida esophagitis: a prospective study of 27 cases. Gastroenterology. 71: 715–719.

Kreijkamp-Kaspers S., Hawke K., Guo L., Kerin G., Bell-Syer S.E., Magin P., Bell-Syer S.V., van Driel M.L. 2017. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst. Rev. 14:7:CD010031.

Kumamoto CA. 2011. Inflammation and gastrointestinal Candida colonization. Curr. Opin. Microbiol. 14(4): 386–391.

Kumaraswamy K.L., Vidhya M., Rao P.K., Mukunda A. 2012. Oral biopsy: oral pathologist’s perspective. J. Cancer Res. Therap. 8(2): 192–198. doi: 10.4103/0973-1482.98969.

Lim C.S.Y., Rosli R., Seow H.F., Chong P.P. 2012. Candida and invasive candidiasis: back to basis. Eur. J. Clin. Microbiol. Infect. Dis. 31: 21–31.

Mahmoudi Rad M., Zafarghandi A.Sh., Amel Zabihi M., Tavallaee M., Mirdamadi Y. 2012. Identification of Candida species associated with vulvovaginal candidiasis by multiplex PCR. Infect. Dis. Obstet. Gynecol. 2012: 872169.

Manolakaki D., Velmahos G., Kourkoumpetis T., Chang Y., Alam H. B., De Moya M. M., Mylonakis E. 2010. Candida infection and colonization among trauma patients. Virulence. 1(5): 367–375.

Marcos-Arias C., Eraso E., Madariaga L., Aguirre J.M., Quindós G. 2011. Phospholipase and proteinase activities of Candida isolates from denture wearers. Mycoses 54(4): e10–16.

Martins N., Ferreira I.C., Barros L., Silva S., Henriques M. 2014. Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment. Mycopathologia. 177 (5–6): 223–240.

Pappas P.G., Kauffman C.A., Andes D.R., Clancy C.J., Marr K.A., Ostrosky-Zeichner L., Reboli A.C., Schuster M.G., Vazquez J.A., Walsh T.J., Zaoutis T.E., Sobel J.D. 2016. Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016. Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 62(4): 409–417.

Patel D, Gillespie B, Sobel J, Leaman D., Nyirjesy P., Weitz M.V., Foxman B. 2004. Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: results of a prospective cohort study. Am. J. Obstet. Gynecol. 190: 644–653.

Patil S., Rao R.S., Majumdar B., Anil S. 2015. Clinical appearance of oral Candida infection and therapeutic strategies. Front Microbiol. 6: 1391.

Patil S., Rao R.S., Majumdar B., Anil S. 2015. Clinical appearance of oral Candida infection and therapeutic strategies. Front Microbiol. 6: 1391. doi: 10.3389/fmicb.2015.01391. PMC 4681845. PMID 26733948.

Pfaller M.A., Diekema D.J. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20: 133–163.

Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Ellis D, Tullio V., Rodloff A., Fu W., Ling T. A., and the Global Antifungal Surveillance Group. 2010. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5- year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J. Clin. Microbiol. 48: 1366–1377.

Pfaller M.A., Messer S.A., Woosley L.N., Jones R.N., Castanheira M. 2013. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cut off values for characterization of geographic and temporal trends of antifungal resistance. J. Clin. Microbiol. 51: 2571–2581.

Richter S.S., Galask R.P., Messer S.A., Hollis R.J., Diekema D.J., Pfaller M.A. 2005. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J. Clin. Microbiol. 43: 2155–2162.

Sekhavat L., Tabatabaii A., Tezerjani F.Z. 2011. Oral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis. J. Infect. Public Health. 4: 95–99.

Sexually Transmitted Diseases Treatment Guidelines 2006. Recommendations and Report. MMWR. 2006, 55, 1-100. http://www.cdc.gov/std/treatment/2006/rr5511.pdf.

Shemer A., Sakka N., Baran R., Scher R., Amichai B., Norman L., Farhi R., Magun R., Brazilai A., Daniel R. 2015. Clinical comparison and complete cure rates of Terbinafine efficacy in affected onychomycotic toenails. J. Eur. Acad. Dermatol. Venereol. 29(3): 521–526.

Singh A., Verma R., Murari A., Agrawal A. 2014. Oral candidiasis: an overview. J. Oral Maxillofac. Pathol. 18 (Suppl. 1): 81–85.

Sobel J.D., Chaim W.,Nagappan V., Leaman D. 2003. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am. J. Obstet. Gynecol. 189: 1297–1300.

Sobel J.D., Wiesenfeld H.C., Martens M, Danna P., Hooton T.M., Rompalo A., Sperling M., Livengood C. 3rd, Horowitz B., Von Thron J., Edwards L., Panzer H., Chu T.C. 2004. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N. Engl. J. Med. 351: 876–883.

Sojakova M., Liptajova D., Borovsky M., Subik J. 2004. Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia. Mycopathologia 157: 163–169.

Staniszewska M., Bondaryk M., Piłat J., Siennicka K., Madga U., Kurzątkowski W. 2012. Czynniki zjadliwości Candida albicans. Przegl. Epidemiol. 66: 629–633.

Stanowisko zespołu ekspertów Polskiego Towarzystwa Ginekologicznego w sprawie leczenia ostrego i nawrotowego grzybiczego zapalenia pochwy i sromu – stan wiedzy na 2008 rok. 2008. Ginekol. Pol. 79: 638–652.

Watson M.C., Grimshaw J.M., Bond C.M.,Mollison J., Ludbrook A. 2002. Oral versus intravaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review. Bjog. 109: 85–95.

Watson, C. J., Grando, D., Garland, S. M., Myers, S., Fairley, C. K., Pirotta, M. 2012. Premenstrual vaginal colonization of Candida and symptoms of vaginitis. J. Med. Microb. 61(11): 1580–1583.

Yang Y.L., Wang A.H., Wang C.W., Cheng W.T., Li S.Y., Lo H.J., TSARY Hospitals. 2008. Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of antimicrobial resistance of yeasts 2006. Diagn. Microbiol. Infect. Dis. 61(2): 175–180.

DOI: http://dx.doi.org/10.17951/c.2018.73.1.61-68
Data publikacji: 2019-06-10 12:49:00
Data złożenia artykułu: 2019-06-10 12:47:05


Total abstract view - 1798
Downloads (from 2020-06-17) - PDF - 0



  • There are currently no refbacks.

Copyright (c) 2019 Marta Dąbrowska, Monika Sienkiewicz, Paweł Kwiatkowski, Michał Dąbrowski

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.